MediWound Ltd.

MediWound Announces Closing of $17. 25 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 5, 2026 (GLOBE NEWSWIRE) - MediWound Ltd. (Nasdaq: MDWD) ("MediWound"), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the closing of its previously announced underwritten public offering of 1,380,000 ordinary shares, including 180,000 ordinary shares issued pursuant to the full exercise of the underwriter's option to purchase additional ordinary shares, at a public offering price of $12.

MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

MediWound Announces $15 Million Bought Deal Offering of Ordinary Shares YAVNE, Israel, November 3, 2026 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that it has entered into an underwriting agreement with H.C.

MediWound to Report Third Quarter 2026 Financial Results Conference Call and Webcast Scheduled for Thursday, November 12 th at 8:30 a.m. Eastern Time YAVNE, Israel, October 29, 2026 -- MediWound Ltd.